Park Ji Young, Park Sung-Bae, Park Heechul, Kim Jungho, Kim Ye Na, Kim Sunghyun
Department of Internal Medicine, Park Clinic, Busan 49267, Korea.
Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan 46252, Korea.
Diagnostics (Basel). 2021 Mar 26;11(4):595. doi: 10.3390/diagnostics11040595.
There have been few reports on the kinetics of hemodialyzed (HD) patients' immune responses in latent tuberculosis infection (LTBI). Therefore, in the present study, messenger ribonucleic acid (mRNA) expression levels of nine immune markers were analyzed to discriminate between HD patients with LTBI and healthy individuals. Nine cytokines and chemokines were screened through relative mRNA expression levels in whole blood samples after stimulation with (MTB)-specific antigens from HD patients with LTBI (HD/LTBI), HD patients without LTBI, and healthy individuals, and results were compared with the QuantiFERON-TB Gold In-Tube (QFT-GIT) test. We confirmed that the C-C motif chemokine 11 (CCL11) mRNA expression level of the HD/LTBI group was significantly higher than the other two groups. Especially, the CCL11 mRNA expression level of the >0.7 IU/mL group in the QFT-GIT test was significantly higher than the <0.2 IU/mL group in the QFT-GIT test and the 0.2-0.7 IU/mL group in the QFT-GIT test ( = 0.0043). The present study reveals that the relative mRNA expression of CCL11 was statistically different in LTBI based on the current cut-off value (i.e., ≥0.35 IU/mL) and in the >0.7 IU/mL group. These results suggest that CCL11 mRNA expression might be an alternative biomarker for LTBI diagnosis in HD patients.
关于血液透析(HD)患者潜伏性结核感染(LTBI)免疫反应动力学的报道很少。因此,在本研究中,分析了9种免疫标志物的信使核糖核酸(mRNA)表达水平,以区分LTBI的HD患者和健康个体。通过用来自LTBI的HD患者(HD/LTBI)、无LTBI的HD患者和健康个体的结核分枝杆菌(MTB)特异性抗原刺激后全血样本中的相对mRNA表达水平,筛选了9种细胞因子和趋化因子,并将结果与结核菌素金标管(QFT-GIT)试验进行比较。我们证实,HD/LTBI组的C-C基序趋化因子11(CCL11)mRNA表达水平显著高于其他两组。特别是,QFT-GIT试验中>0.7 IU/mL组的CCL11 mRNA表达水平显著高于QFT-GIT试验中<0.2 IU/mL组和QFT-GIT试验中0.2 - 0.7 IU/mL组(P = 0.0043)。本研究表明,基于当前临界值(即≥0.35 IU/mL)和>0.7 IU/mL组,LTBI中CCL11的相对mRNA表达在统计学上存在差异。这些结果表明,CCL11 mRNA表达可能是HD患者LTBI诊断的替代生物标志物。